Ipamorelin · Research brief

How Much Ipamorelin Per Day? Daily Dose Guide

Real Peptides Research TeamEditorial

Updated April 15, 202610 min read

45 WORDS

Short answer

Key takeaways

Standard Ipamorelin doses range from 200–300 mcg per injection, administered 2–3 times daily for total daily exposure of 400–900 mcg depending on protocol design.
Ipamorelin's two-hour half-life requires multiple daily injections to maintain pulsatile GH release patterns. Once-daily dosing fails to replicate physiological dynamics.
Injection timing relative to fasting windows, sleep onset, and exercise significantly influences GH pulse amplitude and downstream metabolic effects.
Reconstitution concentration errors are the most common cause of unintended dosing variation. A 5mg vial reconstituted with 2mL yields 2,500 mcg/mL, meaning 200 mcg requires exactly 0.08mL (8 units on an insulin syringe).
Temperature excursions above 8°C and light exposure degrade reconstituted peptides invisibly, reducing effective dose per injection even when the solution appears unchanged.
Twice-daily protocols (morning fasting + pre-sleep) preserve natural GH pulsatility better than three-times-daily administration for most research objectives.

Research protocols for Ipamorelin rarely specify a flat 'daily dose' the way oral medications do. Dosing is structured around injection frequency, timing relative to meals and sleep cycles, and whether the peptide is being administered alone or stacked with other growth hormone secretagogues like CJC-1295. A researcher administering 300 mcg twice daily is working with a fundamentally different pharmacokinetic profile than one administering 200 mcg three times daily, even though the total daily exposure might be similar. The difference lies in pulsatile GH release patterns. Ipamorelin's half-life of approximately two hours means each injection triggers a discrete GH pulse that peaks within 30–45 minutes and returns to baseline within 90–120 minutes.

Our team has worked with researchers exploring Ipamorelin protocols across multiple study designs. The gap between theoretical dosing guidelines and practical implementation comes down to three variables most general resources overlook: injection timing relative to endogenous GH pulse windows, reconstitution accuracy affecting per-injection dosing precision, and whether the protocol accounts for receptor desensitisation at higher frequencies.

How much Ipamorelin per day should research protocols use?

Standard Ipamorelin research protocols use 200–300 mcg per injection administered 2–3 times daily, resulting in total daily exposure ranging from 400–900 mcg. Optimal dosing depends on research objectives. Lower-frequency protocols (twice daily) preserve natural pulsatile GH dynamics, while higher-frequency administration (three times daily) maximises total GH secretion amplitude. Injection timing around fasting windows and sleep onset significantly influences efficacy, making when you dose as important as how much.

Yes, Ipamorelin dosing follows injection-frequency protocols rather than single daily doses. But the reasoning behind that structure is rarely explained. Most peptides are dosed once daily because their half-lives support sustained plasma levels; Ipamorelin's two-hour half-life means it's cleared rapidly, which is precisely why it works. Each injection mimics the body's natural pulsatile GH release rather than creating sustained elevation, which can suppress endogenous production. This article covers standard dosing ranges used in research, how injection frequency affects GH pulse amplitude, what reconstitution errors do to per-injection accuracy, and timing strategies that align Ipamorelin administration with the body's natural GH secretion windows.

Standard Ipamorelin Dosing Protocols in Research

Most published research on Ipamorelin uses doses ranging from 200–300 mcg per subcutaneous injection. The typical protocol structure is twice-daily or three-times-daily administration, meaning total daily peptide exposure falls between 400 mcg (200 mcg × 2) and 900 mcg (300 mcg × 3). These aren't arbitrary ranges. They're derived from dose-response studies showing that Ipamorelin's GH-releasing potency plateaus above 300 mcg per injection without proportional increases in GH pulse amplitude. Going higher doesn't yield meaningfully better results; it just consumes more peptide.

Ipamorelin belongs to the growth hormone secretagogue (GHS) class of peptides, which work by binding to ghrelin receptors (GHSR-1a) in the pituitary gland. This triggers release of stored growth hormone in a pulsatile pattern. A sharp peak followed by return to baseline within 90–120 minutes. The two-hour half-life is a feature, not a limitation: it allows the pituitary to reset between doses, preventing the receptor downregulation and negative feedback loops associated with sustained GH elevation. Research comparing single daily injections to divided doses consistently shows that split dosing preserves physiological GH dynamics better than once-daily boluses.

Reconstitution concentration directly affects dosing precision. If you reconstitute 5mg Ipamorelin with 2mL bacteriostatic water, the resulting solution contains 2.5mg per mL (2,500 mcg/mL). A 200 mcg dose requires 0.08mL; a 300 mcg dose requires 0.12mL. Insulin syringes marked in units (typically 100 units per mL) make this straightforward: 0.08mL equals 8 units, 0.12mL equals 12 units. Errors happen when researchers eyeball volumes or use syringes without clear unit markings. A 50% dosing error at this scale is the difference between 200 mcg and 300 mcg, which changes total daily exposure by 33% across a twice-daily protocol.

Injection Frequency and Timing Considerations

The decision between twice-daily and three-times-daily dosing isn't about total peptide volume. It's about matching injection timing to endogenous GH pulse windows. The body naturally releases growth hormone in pulses throughout the day, with the largest surge occurring 60–90 minutes after sleep onset and smaller pulses triggered by fasting, exercise, and protein consumption. Ipamorelin administered before these natural windows amplifies the existing pulse; administered randomly, it creates an isolated spike that may not align with downstream anabolic signalling pathways.

Most twice-daily protocols use morning fasting administration (upon waking, before breakfast) and pre-sleep administration (30–60 minutes before bed). This timing captures two of the body's strongest endogenous GH windows: the post-sleep trough that rebounds during early waking hours, and the sleep-onset surge. Three-times-daily protocols add a midday or post-workout injection, typically administered at least three hours after the morning dose and three hours before the evening dose to maintain spacing. Tighter spacing. Injections within 90 minutes of each other. Wastes peptide because the pituitary hasn't fully reset from the previous pulse.

Exercise timing creates a strategic opportunity. Resistance training and high-intensity interval training both trigger endogenous GH release through lactate accumulation and metabolic stress. Administering Ipamorelin 15–30 minutes before a training session allows the peptide-induced pulse to peak during the workout, potentially amplifying the exercise-induced GH response. Research hasn't definitively proven synergistic effects, but the physiological logic is sound: you're stacking two GH-releasing stimuli during the same metabolic window.

Reconstitution and Storage Variables Affecting Per-Dose Accuracy

Ipamorelin arrives as lyophilised powder requiring reconstitution with bacteriostatic water before injection. The standard process. Inject water slowly down the vial wall, allow powder to dissolve passively without shaking. Seems simple, but reconstitution concentration directly determines per-injection dosing accuracy. A researcher who reconstitutes 5mg with 1mL instead of 2mL has doubled the solution concentration, meaning their '200 mcg dose' is actually 400 mcg if they're drawing the same volume.

Storage temperature after reconstitution affects peptide stability and, consequently, effective dose per injection over time. Unreconstituted lyophilised Ipamorelin remains stable at −20°C for 12–24 months; once reconstituted, it must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C. Even brief ones. Begin protein denaturation that neither visual inspection nor home testing can detect. A vial left on the counter for six hours might look identical but deliver 70% of its labelled dose per injection due to partial degradation.

Light exposure compounds degradation. Peptides are photosensitive; UV and even bright indoor lighting accelerate breakdown when vials are stored in clear glass under standard refrigerator lighting. Amber vials or aluminium foil wrapping around the vial body prevents this. The practical implication: two researchers using identical 200 mcg protocols might be delivering meaningfully different effective doses if one stores reconstituted peptide in a clear vial under fluorescent light and the other uses amber glass in a dark refrigerator drawer.

Ipamorelin Per Day Daily Dose: Research Protocol Comparison

Protocol Structure	Dose Per Injection	Injections Per Day	Total Daily Exposure	Timing Strategy	Typical Research Application
Low-Frequency	300 mcg	2× daily	600 mcg	Morning fasting + pre-sleep	Metabolic studies, lean mass preservation
Moderate-Frequency	250 mcg	2× daily	500 mcg	Post-wake + pre-bed	General growth hormone dynamics research
High-Frequency	200 mcg	3× daily	600 mcg	Morning, midday, pre-sleep	Recovery studies, injury healing models
Split-Dose with Exercise	300 mcg	2× daily	600 mcg	Pre-workout + pre-sleep	Performance and body composition research
Conservative Protocol	200 mcg	2× daily	400 mcg	Upon waking + evening	Initial dose-finding studies, receptor sensitivity trials

What If: Ipamorelin Dosing Scenarios

What If You Miss a Scheduled Injection?

Administer the missed dose as soon as you remember, then resume the regular schedule from that point forward. If you're within two hours of the next scheduled injection, skip the missed dose entirely and continue with the planned injection. Doubling up within a short window creates overlapping GH pulses that don't enhance the response. Missing a single injection in a multi-week protocol has negligible impact on cumulative outcomes; missing doses consistently (more than two per week) disrupts the pulsatile rhythm that makes Ipamorelin effective. The body's GH axis adapts to predictable stimulation patterns, so erratic dosing reduces receptor sensitivity over time.

What If Reconstituted Peptide Was Left at Room Temperature Overnight?

Discard the vial. Ipamorelin reconstituted with bacteriostatic water begins degrading above 8°C, and an eight-hour temperature excursion at 20–25°C causes irreversible protein denaturation. The solution may still appear clear, but potency has declined by an estimated 30–60% depending on ambient temperature. Visual inspection cannot detect this. Only laboratory mass spectrometry would confirm degradation. Using temperature-compromised peptide means subsequent injections deliver unpredictable doses, invalidating any research data collected. Temperature excursions are the single most common storage error in peptide research.

What If You're Stacking Ipamorelin with CJC-1295?

Reduce per-injection Ipamorelin dose to 200 mcg when co-administering with CJC-1295 (with DAC) at 1–2mg per week. CJC-1295 extends the GH pulse duration by preventing rapid degradation of growth hormone-releasing hormone (GHRH), meaning Ipamorelin's pulse amplitude gets amplified and prolonged when both are active simultaneously. Using 300 mcg Ipamorelin in a stack risks excessive GH elevation beyond physiological ranges. Most research protocols using this combination inject both peptides at the same time points (morning and pre-sleep) to synchronise their mechanisms. Ipamorelin triggers the pulse, CJC-1295 extends it.

The Dosing Truth About Ipamorelin

Here's the honest answer: the emphasis on 'daily dose' in most peptide discussions is fundamentally misplaced when talking about Ipamorelin. This isn't a once-daily medication where you hit a target milligram amount and you're done. It's a pulsatile secretagogue designed to mimic the body's natural GH release pattern, which happens multiple times per day in discrete bursts. Asking 'how much per day' is like asking how much insulin a pancreas releases daily. The total matters less than the timing, frequency, and amplitude of individual secretion events.

Researchers fixated on total daily exposure often make the mistake of consolidating doses into fewer, larger injections to 'simplify' the protocol. A single 600 mcg morning injection is not equivalent to 300 mcg twice daily, even though the arithmetic is the same. The single large dose creates a supraphysiological GH spike followed by 22 hours of minimal activity; the split protocol creates two moderate pulses aligned with the body's endogenous rhythm. The latter preserves receptor sensitivity, avoids negative feedback suppression, and more closely models the physiological state the research is designed to study. If convenience is the priority, Ipamorelin is the wrong peptide. Longer-acting alternatives like CJC-1295 with DAC exist precisely for once-weekly dosing.

The second uncomfortable truth: most dosing errors happen at reconstitution, not administration. A researcher who carefully measures 250 mcg per injection but reconstituted their vial incorrectly is delivering the wrong dose every single time without knowing it. Peptide research demands precision at every step. Lyophilised powder measurement, bacteriostatic water volume, syringe unit calibration, injection timing. There's no margin for approximation. The difference between effective research and wasted peptide often comes down to whether someone took 30 seconds to verify their reconstitution math before the first draw.

Ipamorelin protocols require structured timing, accurate reconstitution, and disciplined storage. Or they fail invisibly. There's no shortcut.

For researchers exploring Ipamorelin alongside other peptides in structured study designs, our CJC1295 Ipamorelin 5MG 5MG blend offers pre-measured ratios designed for twice-daily co-administration. Each peptide in our catalog undergoes small-batch synthesis with exact amino-acid sequencing verification, so the dose you calculate is the dose you're actually delivering. Quality matters when precision is the entire point.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on Ipamorelin indexed in PubMed, listed for research context. Real Peptides supplies Ipamorelin for laboratory research use only.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024. PMID 39043357. doi:10.1016/j.physbeh.2024.114644
The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science, 2024. PMID 38996787. doi:10.1016/j.anireprosci.2024.107550
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014. PMID 25331030. doi:10.1007/s00384-014-2030-8
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 2012. PMID 27186127. doi:10.2147/JEP.S35396
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 2009. PMID 19289567. doi:10.1124/jpet.108.149211
Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters, 2004. PMID 15665799
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778. doi:10.14670/HH-17.707
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001. PMID 11735244. doi:10.1054/ghir.2001.0239

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Standard research protocols use 200–300 mcg Ipamorelin per subcutaneous injection. Doses below 200 mcg produce minimal GH pulse amplitude; doses above 300 mcg show diminishing returns without proportional increases in growth hormone release. Most researchers start at 200 mcg per injection and increase to 250–300 mcg based on study objectives and whether Ipamorelin is being administered alone or stacked with other secretagogues like CJC-1295.

Once-daily Ipamorelin administration is pharmacologically suboptimal due to the peptide's two-hour half-life. A single daily injection creates one isolated GH pulse followed by 22+ hours of minimal activity, failing to replicate the body's natural pulsatile rhythm. Research consistently shows that twice-daily or three-times-daily protocols preserve physiological GH dynamics better than consolidated dosing. If once-daily convenience is required, longer-acting alternatives like modified GRF or CJC-1295 with DAC are more appropriate choices.

Reconstituted Ipamorelin must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation — even a single overnight period at room temperature can reduce potency by 30–60%. Light exposure accelerates degradation; storing vials under bright refrigerator lighting in clear glass compounds the problem. Degraded peptide looks visually identical to fresh solution, so storage discipline is critical. Amber glass vials and dark storage locations preserve stability.

Injection timing relative to fasting windows, sleep onset, and exercise significantly influences GH pulse amplitude. The body's largest natural GH surge occurs 60–90 minutes after sleep onset; administering Ipamorelin 30–60 minutes before bed amplifies this endogenous pulse. Morning fasting administration (before breakfast) captures the post-sleep GH trough rebound. Injecting randomly throughout the day produces isolated pulses that may not align with downstream anabolic pathways, reducing the metabolic impact per injection.

The 200 mcg twice-daily protocol delivers 400 mcg total daily exposure and is typically used in initial dose-finding studies or when stacking with other GH secretagogues. The 300 mcg twice-daily protocol delivers 600 mcg total daily exposure and is more common in metabolic research and body composition studies where maximal per-pulse amplitude is desired. Both preserve pulsatile GH dynamics equally well; the difference is total GH secretion amplitude across the 24-hour cycle.

Reconstitution volume determines solution concentration. If you reconstitute 5mg Ipamorelin with 2mL bacteriostatic water, the resulting concentration is 2.5mg per mL (2,500 mcg/mL). To draw 200 mcg, divide 200 by 2,500 = 0.08mL, which equals 8 units on a standard insulin syringe. For 300 mcg: 300 ÷ 2,500 = 0.12mL (12 units). Errors occur when researchers don't account for actual reconstitution volume or use syringes without clear unit markings.

Yes — reduce Ipamorelin to 200 mcg per injection when co-administering with CJC-1295 (with DAC). CJC-1295 extends GH pulse duration by preventing GHRH degradation, so Ipamorelin's pulse gets amplified and prolonged. Using 300 mcg Ipamorelin in this stack can push GH levels beyond physiological ranges. Most combination protocols inject both peptides at the same time points (morning and pre-sleep) to synchronise their complementary mechanisms — Ipamorelin triggers the pulse, CJC-1295 extends it.

Published research typically caps total daily Ipamorelin exposure at 900 mcg (300 mcg × 3 injections). Doses above this threshold don't produce proportional increases in GH secretion due to receptor saturation and increased likelihood of desensitisation with chronic use. Safety is well-established at standard research doses; Ipamorelin shows minimal impact on cortisol, prolactin, or acetylcholine — side effects common with earlier GH secretagogues like GHRP-6. Exceeding 900 mcg daily offers no research advantage and wastes peptide.

Ipamorelin has a plasma half-life of approximately two hours. GH pulse amplitude peaks 30–45 minutes post-injection and returns to baseline within 90–120 minutes. This rapid clearance is intentional — it allows the pituitary to reset between doses, preventing the receptor downregulation that occurs with sustained GH elevation. The short half-life is why Ipamorelin requires multiple daily injections rather than once-daily dosing like longer-acting peptides.

Most research protocols use fixed per-injection doses (200–300 mcg) regardless of body weight, because Ipamorelin acts on pituitary receptors — a mechanism independent of body mass. Unlike exogenous GH, which is often dosed proportionally to weight, secretagogues trigger the body's own GH release, so receptor saturation occurs at similar peptide concentrations across different body sizes. Weight-based dosing is occasionally used in veterinary research but is not standard practice in human peptide studies.

Typical Ipamorelin research cycles run 8–12 weeks, followed by a 4–6 week washout period to prevent receptor desensitisation. Continuous use beyond 12 weeks without breaks can reduce per-injection efficacy as ghrelin receptors downregulate in response to repeated stimulation. The washout period allows receptor density to normalise. Some long-term studies use lower-frequency dosing (twice weekly instead of twice daily) to maintain chronic exposure without desensitisation, but this sacrifices the pulsatile dynamics that make Ipamorelin unique.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA